Investors are always looking for stocks that are poised to beat at earnings season and CymaBay Therapeutics Inc. CBAY may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.
That is because CymaBay Therapeuticsis seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings—with the most up-to-date information possible—is a pretty good indicator of some favorable trends underneath the surface for CBAY in this report.
In fact, the Most Accurate Estimate for the current quarter is currently at a loss 24 cents per share for CBAY, compared to a broader Zacks Consensus Estimate loss of 25 cents cents per share. This suggests that analysts have very recently bumped up their estimates for CBAY, giving the stock a Zacks Earnings ESP of +4.00% heading into earnings season.
CymaBay Therapeutics Inc. Price and EPS Surprise
CymaBay Therapeutics Inc. Price and EPS Surprise | CymaBay Therapeutics Inc. Quote
Why is this Important?
A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10 year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).
Given that CBAY has a Zacks Rank #3 (Hold) and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Clearly, recent earnings estimate revisions suggest that good things are ahead for CymaBay Therapeutics, and that a beat might be in the cards for the upcoming report.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CymaBay Therapeutics Inc. (CBAY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research